Gelmetix Limited news

Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round.

Following successful in-vivo and pre-clinical studies, the University of Manchester spin-out will now use the additional capital to fund its upcoming first-in-human (FIH) trial and preparing for the pivotal study. The Series C investment was led by Seneca Partners, while the £3 million Series B inves

We’re delighted to announce that  on 3rd December, with total prize winnings of €210,000 available among the best performers. The seven finalists represented best-in-class innovations in biotech across Europe, having been selected from hundreds of entrants.

EIT Health Catapult is a unique competition and training programme that showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe. The programme recognises and awards the

• Stemmatters and Gelmetix have established an agreement to develop an innovative hydrogel based device for the treatment of cartilage lesions.
• The partnership established focuses on the pre-clinical development of the new device towards clinical studies in human patients and subsequent market authorization.
• The new medical device aims to ensure a significant advance in the treatment of cartilage lesions, by seeking to provide a high treatme

We are proud to announce that our rebranding process is now complete. Gelexir Healthcare, known for being a spin off of the University of Manchester and for its cutting edge R&D work on non-invasive treatments for Chronic Low Pain, officially becomes Gelmetix.

This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: chronic low back pain, small joints osteoarthritis and knee osteoarthritis, and to enable Ge